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ABSTRACT
Objective: In clinical trials of dabigatran and
rivaroxaban for stroke prevention in atrial fibrillation
(AF), drug eligibility and dosing were determined using
the Cockcroft-Gault equation to estimate creatine
clearance as a measure of renal function. This cross-
sectional study aimed to compare whether using
estimated glomerular filtration rate (eGFR) by the
widely available and widely used Modified Diet in Renal
Disease (MDRD) equation would alter prescribing or
dosing of the renally excreted new oral anticoagulants.
Participants: Of 4712 patients with known AF within
a general practitioner-registered population of 930 079
in east London, data were available enabling renal
function to be calculated by both Cockcroft-Gault and
MDRD methods in 4120 (87.4%).
Results: Of 4120 patients, 2706 were <80 years and
1414 were ≥80 years of age. Among those ≥80 years,
14.9% were ineligible for dabigatran according to
Cockcroft-Gault equation but would have been judged
eligible applying MDRD method. For those <80 years,
0.8% would have been incorrectly judged eligible for
dabigatran and 5.3% would have received too high a
dose. For rivaroxaban, 0.3% would have been
incorrectly judged eligible for treatment and 13.5%
would have received too high a dose.
Conclusions: Were the MDRD-derived eGFR to be
used instead of Cockcroft-Gault in prescribing these
new agents, many elderly patients with AF would either
incorrectly become eligible for them or would receive
too high a dose. Safety has not been established using
the MDRD equation, a concern since the risk of major
bleeding would be increased in patients with
unsuspected renal impairment. Given the potentially
widespread use of these agents, particularly in primary
care, regulatory authorities and drug companies should
alert UK doctors of the need to use the Cockcroft-Gault
formula to calculate eligibility for and dosing of the
new oral anticoagulants in elderly patients with AF and
not rely on the MDRD-derived eGFR.
INTRODUCTION
Dabigatran and rivaroxaban are the ﬁrst new
oral anticoagulants to be licensed by the
European Medicines Agency for the
prevention of stroke in patients with atrial ﬁb-
rillation (AF). Both agents have recently been
approved by the National Institute for Health
and Clinical Excellence and the Scottish
Medicines Consortium.1–4 This follows the
publication of large multicentre randomised
clinical trials demonstrating superiority com-
pared with warfarin in stroke prevention with
dabigatran 150 mg twice daily, and non-
inferiority compared with warfarin with lower
dose dabigatran (110 mg twice daily) and riv-
aroxaban.5 6 Anticoagulation is now recom-
mended for the vast majority of patients with
AF and preference is given to the new agents
as used in the trials over warfarin in the most
recent European Society of Cardiology
guidelines.7
Both dabigatran and rivaroxaban are
excreted by the kidneys: in the case of dabiga-
tran renal clearance is 80%8 and with rivarox-
aban it is approximately 30% as the active
molecule.9 Drug accumulation potentiating
anticoagulant effects occurs with declining
renal function. This is of clinical relevance,
given that the population at risk with AF
tends to be older, often with associated vascu-
lar risk factors that cluster with renal
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This is a large community-based, cross-sectional
study of over 4000 patients with atrial fibrillation
(AF), in almost 90% of whom renal function
could be estimated by both the Cockcroft-Gault
method used in the clinical trials of the new oral
anticoagulants and the Modified Diet in Renal
Disease-derived estimated glomerular filtration
rate used in routine clinical practice.
▪ The study describes the potential rather than
observed risks of major bleeding resulting from
inadvertent overprescribing of the new oral antic-
oagulants to elderly patients with AF and unsus-
pected renal impairment.
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impairment. Assessing creatinine clearance (CrCl) for-
mally through isotope testing is impractical in this
cohort, and estimated glomerular ﬁltration rate (eGFR)
is now widely used as a surrogate measure of renal func-
tion in both primary and secondary care. The eGFR is
calculated using the Modiﬁed Diet in Renal Disease
(MDRD) equation and is based on serum creatine, age,
gender and ethnicity.10 An alternative estimate of renal
function (the estimated creatinine clearance (eCrCl)) is
based on the Cockcroft-Gault equation which requires
the inclusion of weight in addition to serum creatinine,
age and gender.10 The difference is important as serum
creatinine is a less reliable predictor of CrCl at extremes
of body mass (creatine synthesis is dependent on muscle
bulk). In clinical trials of the new oral anticoagulants in
stroke prevention in AF renal function was estimated by
the Cockcroft-Gault equation and patients with eCrCl
values <30 mL/min were excluded.5 6
The Summary of Product Characteristics (SPC) for dabi-
gatran11 recommends that this agent is contraindicated in
patients with a CrCl <30 mL/min. Patients at increased
risk of haemorrhage (patients with a CrCl of 30–50 mL/
min are listed as one such group) should be individually
considered for lower dose dabigatran therapy (110 mg
twice daily) and this reduced dose is recommended for all
patients of ≥80 years with a CrCl ≥30 mL/min. According
to its SPC,9 rivaroxaban is contraindicated in patients with
a CrCl of <15 mL/min and the dose should be reduced
from 20 to 15 mg daily in those with a CrCl of 15–49 mL/
min. In each SPC the recommended method for estima-
tion of renal function as CrCl is Cockcroft-Gault.
Introduction of dabigatran into clinical practice in other
countries has been associated with several reports of major
haemorrhage, particularly in elderly patients with
impaired renal function,12 and the Medicines and
Healthcare products Regulatory Agency (MHRA) has
recently issued two sets of advice with regard to bleeding
risks.13 14 It recommends that renal function be checked
before starting dabigatran and that it should be reassessed
at least annually in patients >75 years or with renal impair-
ment or if a decline in renal function is suspected during
treatment. However, although referring to CrCl, the
method of assessment of renal function is not stated. In
the UK, all biochemistry laboratories provide an
MDRD-derived eGFR (mL/min/1.73 m2) in keeping with
national guidance.15 Many clinicians will use this result to
estimate renal function at initiation or follow-up of the
new oral anticoagulants.
This study aimed to compare the two methods of
assessment of renal function to determine whether sub-
stitution of Cockcroft-Gault by MDRD would affect
either the selection of patients for the new oral anticoa-
gulants or the dose of dabigatran or rivaroxaban these
patients were prescribed. This is important to establish
because the bleeding risk of warfarin is increased in
patients with renal impairment16 and the bleeding risks
of the new agents might be even higher since, unlike
warfarin, they are excreted through the kidneys and
therefore accumulate with renal dysfunction. Moreover,
and again unlike warfarin, they lack an antidote in the
event of bleeding.
METHODS
The study was set in the three geographically contiguous
east London primary care trusts (PCTs) of Newham,
Tower Hamlets and City and Hackney, with a combined
general practitioner (GP)-registered population of
930 079 in April 2012. The populations of these PCTs
come from among the eight most socially deprived local-
ities in Britain, with more than 50% of the population
being of non-white ethnic origin. In June 2012, demo-
graphic and clinical data were obtained from 137/141
general practices in east London covering more than
98% of the GP-registered population in the three PCTs.
All data were anonymous and managed according to the
UK NHS information governance requirements.
Clinical and demographic data collection
Practice computer databases were interrogated using
Egton Medical Information Systems Web software. All
adult patients (18 years and over) with a Read code for
AF were included in the study.
Demographic variables extracted included age, gender
and ethnicity. Ethnicity was self-reported by patients and
collapsed into ﬁve categories: white (British, Irish, other
white); south Asian (Bangladeshi, Indian, Pakistani, other
Asian, white and Asian); black (African, Caribbean, white
and Caribbean, white and African); other (Chinese, other
mixed, and any other recorded ethnic group) and not
stated.
Clinical variables included weight and the latest serum
creatinine value (in μmol/L) within the past 2 years.
Different methods for measuring the serum creatine are
used in the study area; however, as we report else-
where,17 differences between laboratory techniques
result in negligible variations in estimates of renal func-
tion which we do not consider will affect its overall
classiﬁcation.
Renal function
For each patient in the study, renal function was calcu-
lated using both the Cockcroft-Gault and the MDRD
methods. Ethnicity recording was available for the entire
cohort and the black ethnicity correction factor was
added to the MDRD formula prior to analysis.
eGFR using MDRD=186×(creatine/
88.4)−1.154×age−0.203×(0.742 if female)×(1.21 if black). The
result is expressed in mL/min/1.73 m2.
eCrCl using Cockcroft-Gault=(140−age)×weight in
kg×1.23 (×0.85 if female)×creatine. The result is
expressed in mL/min.
Statistical analysis
All statistical analyses were performed using Stata V.12
(StataCorp LP). Concordance between the two methods
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of measurement was examined using Bland-Altman
plots. Each result was entered into one of several cat-
egories of renal function that would be used for selec-
tion for or dosing of dabigatran or rivaroxaban except
that a category of eCrCl of ≥70 mL/min was also
included to assess whether any patient with relatively
normal renal function would be differently classiﬁed so
as to affect selection or dosing. The proportions of cases
in each category of CrCl estimated by Cockcroft-Gault
equation which would be misattributed, were the MDRD
equation to be used, were calculated.
Logistic regression was used to examine the odds of
the MDRD-based categorisation of eGFR being different
to CrCl estimated by the Cockcroft-Gault method, so as
to affect selection for or dosing of dabigatran or rivarox-
aban, according to age, sex, weight and clustering by
general practice.
RESULTS
A total of 4712 patients with AF were identiﬁed. Their
demographic features by gender, ethnicity and age are
shown in table 1. Of these, 419 had missing serum creat-
ine values, one had a serum creatine value below
30 μmol/L, 268 had a missing value for weight and 96
individuals were missing both creatinine and weight,
leaving 4120 (87.4%) patients with sufﬁcient data to
allow calculation of renal function by both
Cockcroft-Gault and MDRD methods.
A Bland-Altman plot (ﬁgure 1) demonstrates that,
relative to Cockcroft-Gault, MDRD slightly underesti-
mates renal function at higher levels and tends to over-
estimate at lower levels.
To assess the impact of the method used for estima-
tion of renal function on potential dosing of the new
anticoagulants, patients were categorised by renal func-
tion as estimated by Cockcroft-Gault equation and the
proportions given would change categories if estimated
by MDRD are given in tables 2 and 3. The results are
shown for the entire cohort for rivaroxaban and separ-
ately for those <80 and ≥80 years for dabigatran since
age affects the dosing of the latter.
Dosing dabigatran
Dabigatran is contraindicated if the eCrCl is
<30 mL/min and its dosage should be reduced (from
150 to 110 mg twice daily) in those ≥80 years. For those
<80 years, dose reduction should be considered on an
individual basis in those with a Cockcroft-Gault eCrCl of
30–50 mL/min, particularly if there is an additional
bleeding risk. Table 2 shows that of the 1414 patients
with AF 80 years of age or older, 211 (14.9%) were ineli-
gible for dabigatran because of an eCrCl <30 mL/min
according to Cockcroft-Gault, but would have been
judged eligible for dabigatran as they had an eGFR
≥30 mL/min/1.73 m2 by MDRD. The proportion of
patients being misclassiﬁed in the opposite direction (ie,
being judged ineligible for treatment due to their
MDRD eGFR) was much smaller at 0.9%. For the 2706
patients younger than 80 years there was a small propor-
tion of misclassiﬁcation in either direction with around
1% being incorrectly judged eligible and 10% poten-
tially receiving too high or too low a dose.
Dosing rivaroxaban
Rivaroxaban should be dose reduced to 15 mg daily (from
20 mg daily) if the Cockcroft-Gault eCrCl is
15–49 mL/min and is contraindicated if it is <15 mL/min.
Table 3 shows that of the 4120 patients with AF, 11 (0.3%)
were ineligible for rivaroxaban because of an eCrCl
<15 mL/min according to Cockcroft-Gault, but would
have been judged eligible for rivaroxaban as they had an
eGFR ≥15 mL/min/1.73 m2 by MDRD. A further 556
patients (13.5%) would be judged to require a reduced
dose of rivaroxaban because of an eCrCl between 15 and
<50 mL/min according to Cockcroft-Gault, but no reduc-
tion in dose would have appeared necessary as they had an
eGFR ≥50 mL/min/1.73 m2 by MDRD. The proportions
of patients being misclassiﬁed in the opposite direction
(ie, either being judged ineligible for treatment or
Table 1 Summary of demographic and clinical features of
patients with atrial fibrillation (AF; N=4712)
Demographic
variables
Patients
with AF
Percentage
of total
population
PCT
City and Hackney 1670 36
Newham 1644 35
Tower hamlets 1398 30
Sex
Female 2122 44
Male 2590 56
Ethnic group
White 3450 73
South Asian 481 10
Black 491 11
Other 209 4
Not stated/refused 62 1
Missing 119 2
Age (years)
18–35 62 2
35–44 132 3
45–54 360 8
55–64 684 15
65–74 1092 23
75–84 1495 32
85+ 887 19
Weight (kg)
<60 689 15
≥60 3755 80
Weight missing 268 6
Clinical variables recorded
Weight 4444 94
Creatinine 4292 91
PCT, primary care trust.
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requiring a reduced dose due to their MDRD eGFR) were
smaller at 0.1% and 4.5%, respectively.
Effect of other variables on differences between
eCrCl and eGFR
As shown in the regression analysis in table 4, those
aged ≥80 years were more than 15-fold (OR=15.41; 95%
CI 10.00 to 23.75) more likely to be incorrectly judged
eligible for dabigatran by MDRD (as Cockcroft-Gault
judged them ineligible). Those whose weight was <60 kg
were eightfold (OR=8.22; 95% CI 6.05 to 11.18) more
likely to be incorrectly judged eligible for dabigatran
and a signiﬁcant but smaller effect was also seen in
women (OR=1.45; 95% CI 1.05 to 2.00). For rivaroxa-
ban, patients ≥80 years had almost 10 times (OR=9.71;
95% CI 1.06 to 88.5) the odds of being incorrectly
judged eligible by MDRD. Those whose weight was
<60 kg were more than 12-fold (OR 12.73; 95% CI 1.85
to 87.53) more likely to be incorrectly judged eligible
for rivaroxaban. The age effect (ie, ≥80 years) on renal
function assessment was evident even in patients with
MDRD-derived eGFR values ≥70 mL/min/1.73 m2: of
311 such patients 27% had a Cockcroft-Gault eCrCl of
<50 mL/min (data not shown).
DISCUSSION
Our analysis of more than 4000 patients with AF in
primary care shows that there would be clinically import-
ant potential risks to prescribing practice for the ﬁrst
Figure 1 Agreement between Cockcroft-Gault and Modified Diet in Renal Disease estimation (N=4120).
Table 2 Treatment decisions made about dabigatran using the eGFR from the MDRD method assuming the eCrCl from the
Cockcroft-Gault (CG) method is the gold standard
Treatment recommendations
for dabigatran
Measured values by
CG and MDRD methods
Patients
<80 years of age
Patients
≥80 years of age
N Per cent N Per cent
Undertreated—contraindication incorrectly
identified by MDRD
CG ≥30 and MDRD <30 41 1.5 13 0.9
Underdosed—dose reduction incorrectly
identified by MDRD
CG ≥50 and MDRD 30–<50 149 5.5 – –
Correctly treated 2351 86.9 1190 84.1
Overdosed—recommendation for dose
reduction missed by MDRD
CG 30–<50 and MDRD ≥50 144 5.3 – –
Overtreated—contraindication missed by MDRD CG <30 and MDRD ≥30 21 0.8 211 14.9
All patients 2706 100.0 1414 100.0
eCrCl, estimated creatine clearance; eGFR, estimated glomerular filtration rate; MDRD, Modified Diet in Renal Disease.
4 MacCallum PK, Mathur R, Hull SA, et al. BMJ Open 2013;3:e003343. doi:10.1136/bmjopen-2013-003343
Open Access
two new oral anticoagulants licensed in the UK for the
prevention of stroke if the widely available MDRD eGFR
formula were used instead of Cockcroft-Gault to estimate
CrCl, especially in patients aged 80 years and over.
These patients are a very important group for whom
there are major attractions for the new oral anticoagu-
lants because of their ease of use as well as their efﬁcacy
and safety evident in clinical trials. AF is both particu-
larly prevalent and an important cause of stroke in this
patient group but they are also more susceptible to the
bleeding complications of anticoagulant therapy.18 Of
the patients who are 80 years and over, in whom the
bleeding risk appears highest, 15% would be incorrectly
judged eligible for dabigatran based on the MDRD
rather than the Cockcroft-Gault formula. Similar ﬁnd-
ings were reported from a recent Swedish study examin-
ing surrogates of renal function and drug dosing.19
A proportion of patients would receive too high a dose
of rivaroxaban had the MDRD formula been used. This
suggests that the Cockcroft-Gault formula should be
used for all patients who are 80 years or more (69% of
whom had an eCrCl <50 mL/min compared with 15.9%
of those under 80 years) although in clinical practice it
would be simpler and safer to adopt this approach for
all patients regardless of age. This may be particularly
the case since a second factor, being underweight
(<60 kg), also independently increased the chance of
incorrectly being judged eligible for these agents.
The absolute risk of major bleeding on warfarin
in recent registries20 and contemporary trials5 6 is about
1–3% per year and might therefore increase to approxi-
mately 4% annually in those with renal impairment.16
The risks and beneﬁts of warfarin are not always clear in
this setting in which the stroke risk is also increased.21 22
Although the safety of both dabigatran and rivaroxaban
appears satisfactory down to a CrCl of 30 mL/min5 23
clinical data are lacking for patients with CrCl values
<30 mL/min and the recommendation for dosing rivar-
oxaban in those with an eCrCl of 15–30 mL/min is
based on pharmacokinetic modelling. In a meta-analysis
of the impact of impaired renal function on bleeding in
patients receiving another form of anticoagulation that
is renally excreted—the low-molecular-weight heparin,
enoxaparin—therapeutic doses were associated with an
almost fourfold increase in major bleeding risk in those
with a CrCl of 30 mL/min or less compared with those
with a CrCl >30 mL/min.24 From our data and depend-
ing on the precise impact of dabigatran, we estimate that
of 1000 patients of 80 years or more with AF who might
be treated with this agent, approximately 150 with an
eCrCl <30 mL/min would be inappropriately treated
(because eGFR ≥30 mL/min/1.73 m2) and about 20
might develop major bleeding annually as a result. Many
clinicians will use their judgement and prescribe or dose
on the side of caution at thresholds of eGFR (eg, at or
around 30 mL/min/1.73 m2). We believe that using the
Table 4 OR for likelihood of being over treated due to a contraindication being missed by MDRD adjusted for age, sex and
weight (all variables adjusted for one another)
Variable
Dabigatran Rivaroxaban
OR (95% CI) p Value OR (95% CI) p Value
Male (ref) 1 1
Female 1.45 (1.05 to 2.00) 0.024 1.65 (0.26 to 10.45) 0.593
Age (years)
<80 1 1
≥80 15.41 (10.00 to 23.75) <0.001 9.71 (1.06 to 88.5) 0.044
Weight (kg)
≥60 1 1
<60 8.22 (6.05 to 11.18) <0.001 12.73 (1.85 to 87.53) 0.01
MDRD, Modified Diet in Renal Disease.
Table 3 Treatment decisions made about rivaroxaban using the eGFR from the MDRD method assuming the eCrCl from the
Cockcroft-Gault (CG) method is the gold standard
Treatment recommendations for rivaroxaban
Measured values by CG
and MDRD methods
All patients
N
Per
cent
Undertreated—contraindication incorrectly identified by MDRD CG ≥15 and MDRD <15 5 0.1
Underdosed—dose reduction incorrectly identified by MDRD CG ≥50 and MDRD 15–<50 183 4.4
Correctly treated 3365 81.7
Overdosed—recommendation for dose reduction missed by MDRD CG 15–<50 and MDRD ≥50 556 13.5
Overtreated—contraindication missed by MDRD CG <15 and MDRD ≥15 11 0.3
All patients 4120 100.0
eCrCl, estimated creatine clearance; eGFR, estimated glomerular filtration rate; MDRD, Modified Diet in Renal Disease.
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Cockcroft-Gault equation in at-risk groups would better
allow both appropriate dosing (avoiding under-dosing)
and minimise overanticoagulation.
The four-variable MDRD eGFR is provided alongside
serum creatinine for all laboratory analyses within the UK
and is the basis of much prescribing in primary and sec-
ondary care. The British National Formulary (BNF;
September 2012)25 recommends use of eGFR for dosing
of dabigatran and rivaroxaban in AF. In October 2012, the
electronic BNF entry for dabigatran was altered to include
the manufacturer’s recommendation that the Cockcroft-
Gault method should be used to calculate CrCl. Our ana-
lysis reinforces the need for clinicians to use the
Cockcroft-Gault equation when prescribing these agents.
The selection of the method to estimate renal function
in prescribing medications that are excreted by the kidneys
is not new to controversy—the equations are intended for
the identiﬁcation of chronic kidney disease (CKD) rather
than as tools for pharmacokinetic modelling, and their
accuracy and utility are questionable in those with a true
GFR of >60 mL/min/1.73 m2. Serum creatinine varies
depending on the assay used, diet, muscle mass and body
size. Equations are only useful when kidney function is
stable, and drugs with a narrow therapeutic index are often
better dosed on more formal assessment of function in
those who appear to have CKD. Trials of the new oral antic-
oagulants have used the Cockcroft-Gault equation to calcu-
late CrCl,5 6 as it is practical and has been widely used for
this purpose in the past. The more widely available and
better-performing MDRD formula and a newer CKD-EPI
formula have both been tested as tools for dosing
drugs.10 26 A number of studies have reported the MDRD
equation as leading to higher doses being used when com-
pared with Cockcroft-Gault,27 a ﬁnding consistent with our
own. We advocate caution over potential adverse effects
related to inappropriate dosing when using MDRD com-
pared with Cockcroft-Gault. Each equation is recognised to
either overstate (MDRD) or understate (Cockcroft-Gault)
renal function compared with formal measurement in
those >65 years (a key constituency for oral anticoagulant
use). Both equations are uncorrected for body surface area
in those at the extremes of body weight. It is worth empha-
sising that the creatinine assay used and the population
studied may in itself lead to variation—east London’s multi-
ethnic (>50% non-white ethnic origin) population is not
typical of the UK as a whole.
The convenience and efﬁcacy of the new anticoagulants
mean that they may be considered for many of the esti-
mated 1 million people with AF in the UK (based on a
1.5–2% prevalence in the general population)18 who are
thought to require anticoagulation, only approximately
50% of whom are currently prescribed warfarin.28–30 Our
ﬁndings, therefore, may apply to a large number of
patients and are particularly relevant to the elderly
(≥80 years), all of whom should be considered for treat-
ment with oral anticoagulants in the absence of a contra-
indication and with one of the new agents in broad
preference to warfarin according to recent European
Society of Cardiology guidelines.7 Although different
methods of measurement of renal function appear to be
predictive of bleeding risk in elderly patients on war-
farin,31 until evidence is provided that it is safe to use the
MDRD formula rather than Cockcroft-Gault, it is import-
ant that clinicians and pharmacists are aware that use of
the eGFR may expose patients to increased risks of bleed-
ing. This is particularly pertinent to primary care because
GPs will increasingly take responsibility for selection of the
new oral anticoagulants with eligibility and dose adjust-
ment according to measurement of renal function.
Although in hospital practice there is familiarity with using
the Cockcroft-Gault method of calculation of CrCl, for
example, for dosing of aminoglycosides, this is not the
case for drugs that are used in primary care. This issue
requires further clariﬁcation by the MHRA. Drug compan-
ies too should alert clinicians to the importance of using
the Cockcroft-Gault method of calculation of CrCl for all
patients being considered for or receiving dabigatran or
rivaroxaban for stroke prevention in AF.
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